- Prof Patrick Johnston: Co-Founder
Patrick Johnston is a Professor of Oncology at Queen’s University Belfast (QUB) and was appointed Dean of the School of Medicine & Dentistry and Director of the Institute of Health Sciences at QUB in 2007. He received his MB BCh degree in Medicine from University College Dublin and completed an internship at the Mater and St James’s University Teaching Hospitals, Dublin in 1983. From 1985-1987 he pursued his initial training in Oncology and Haematology in the Mater Hospital, University College Dublin, during which time he attained his doctoral degree in Medicine. Since 1996 he has led the development of a comprehensive cancer centre for Northern Ireland encompassing a state-of-the-art Clinical Cancer Centre (£65 million) at Belfast City Hospital, and a £25 million research centre at QUB. He has led the development of many international research collaborations, including the creation of the NCI–All Ireland Cancer Consortium. Professor Johnston has published over 190 peer review articles and co-edited 5 textbooks. He sits on a number of national and international scientific Boards, and is on the editorial Boards of several leading international oncology journals.
- Prof Paul Harkin: President and Managing Director / Co-Founder
Paul Harkin is a Professor in Molecular Oncology within the Cancer Research Centre at Queen's University Belfast. He has been a Research Fellow in Medicine at Harvard Medical School and the Massachusetts General Hospital where he developed his interest in the emerging field of Functional Genomics. Professor Harkin has published his work in some of the world's leading research journals and is a regular guest speaker at national and international conferences and research institutions. He sits on several National committees and funding boards and acts as a reviewer for a number of major research journals.
- Dr Richard Kennedy MD PhD:VP of Experimental Medicine
Dr Richard Kennedy is the Vice President of Experimental Medicine, he is responsible for managing the research group focusing on novel biomarker and cancer target discovery and development. He is a member of the Scientific Advisory Board of Breast Cancer Campaign UK and the Cancer Research UK Biomarker program. He is a reviewer on the Technologies Board for Enterprise Ireland and for the NHS Technologies assessment Committee in the UK. Prior to Almac Dr. Kennedy worked as an Instructor in Oncology at Harvard Medical School where he specialised in translational cancer research and continues to work as a Medical Oncologist at Belfast City Hospital, UK.
- Dr. Karl Mulligan PhD: VP of Operations
Karl Mulligan joined Almac Diagnostics as the senior company manager at its formation in August 2003. He is responsible for the Global Operations of Almac Diagnostics and the development of the proprietary DSA™ research tool product line. Prior to Almac he was a Senior Research Fellow in the Department of Oncology, Queens University, Belfast, UK.
- Mr Michael Sloan: VP Business Development
Michael Sloan has a BSC in Commerce and MSC in Corporate Leadership and was educated in the University of Birmingham, Napier University, Scotland and the Ivey Business School, Canada.
Michael has over 15 years experience in managing sales and marketing teams in the biotech and medical device sector. He has worked in both start up and multinational companies. He formerly worked for Smith and Nephew as Managing Director of subsidiary BSN Medical UK and joined Almac in 2005 as VP Business Development for Almac Diagnostics.